



ABLYNX IDENTIFIES NOVEL NANOBODIES[®] ACHIEVING SECOND MILESTONE IN PROCTER & GAMBLE COLLABORATION

GHENT, Belgium, 18 June 2007 – Ablynx, the pioneer in the discovery and development of Nanobodies[®] has announced that its collaboration agreement with Procter & Gamble Pharmaceuticals Inc. (P&GP), a division of The Procter & Gamble Company, has reached a second milestone. Ablynx has discovered novel Nanobodies[®] against a second target for possible new treatments in the musculoskeletal area. The first milestone under this collaboration was achieved in December 2006 and was also a target for musculoskeletal diseases.

Ablynx's unique and patented Nanobody[®] technology has been used to rapidly identify a highly diverse and potent panel of Nanobodies[®] against one of the targets exclusive to the collaboration, triggering a second undisclosed milestone payment.

Hennie R. Hoogenboom, PhD, Chief Scientific Officer at Ablynx, said:

"We are delighted to have met another important milestone as part of our on-going collaboration with Procter & Gamble. This is yet another important validation of the speed at which our Nanobody[®] technology platform can deliver high quality Nanobodies[®]. We are very excited to advance this programme to the next stage together with Procter & Gamble."

Kevin E. Driscoll, PhD, Director New Technology Development at P&GP added:

"We are very pleased with the progression of our collaboration with Ablynx. We are a step closer towards the goal of producing Nanobody[®] development candidates in this very important area of musculoskeletal diseases."

As part of this on-going collaboration Ablynx is responsible for discovering Nanobodies[®] that meet an agreed product profile. P&GP is responsible for the pre-clinical and clinical development of Nanobodies[®], as well as the commercialization of any resulting drug products.

Ablynx' strategy is to build a diverse and broad portfolio of therapeutic Nanobodies[®] based on strategic partnerships as well as on its own internal discovery pipeline. In addition to the collaboration with P&GP, Ablynx has ongoing research collaborations and significant, multi-target partnerships with several other major pharmaceutical companies, including Boehringer Ingelheim, Novartis and Wyeth.

-ends-

About Ablynx - www.ablynx.com

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies[®], a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases. Ablynx is developing a portfolio of Nanobody[®]-based therapeutic programmes in a number of major disease areas, including inflammation, thrombosis, oncology and Alzheimer's disease. Already Ablynx has generated Nanobodies[®] against more than hundred different disease targets. The company and its collaborators have obtained positive *in vivo* efficacy data from pre-clinical studies in five major therapeutic programmes in four disease areas. Importantly, in advanced pre-clinical studies, Ablynx has shown *in vivo* the absence of any detectable immunogenicity for its Nanobody[®] development candidates. Ablynx progressed its first programme, an anti-thrombotic (ALX-0081) into phase I beginning of this year and two other programmes are in advanced preclinical development.

Ablynx has ongoing research collaborations and significant, multi-target partnerships with several major pharmaceutical companies, including Boehringer Ingelheim, Novartis, P&G Pharmaceuticals and Wyeth. In parallel Ablynx continues to advance its own Nanobody[®] research and development programmes with the goal to build a unique proprietary pipeline.

Nanobody[®]-based therapeutics represent a major potential commercial opportunity as they combine the beneficial features of conventional antibodies, with desirable properties of small-molecule drugs. Because they are derived from naturally-occurring heavy-chain antibodies, Nanobodies[®] have exceptional protein stability and can be administered in a variety of ways (injected, orally, in sprays or creams), thus overcoming the delivery issues associated with full-sized antibodies, that can typically only be delivered by injection. In addition, because of their unique structure they can also address therapeutic opportunities that are beyond the reach of conventional antibodies or their fragments, for example targeting epitopes such as receptor clefts, enzyme active sites and viral canyon sites. Nanobodies[®] manufactured in micro-organisms also presents a significant cost advantage in comparison to production methods for conventional antibodies.

Ablynx holds the dominant patent position in the field of Nanobodies[®]. It has exclusive and worldwide rights to more than forty families of granted patents and pending patent applications, including the patents covering the basic structure, composition, preparation and uses of Nanobodies[®] (the 'Hamers patents' which have been granted in major territories including the US, Europe and Japan). All products, including therapeutics, that contain Nanobodies[®] are covered by these patents.

Headquartered in Ghent, Belgium, Ablynx has raised over €70 million (over US\$87,5 million) from a strong investor consortium including Abingworth Management (UK), Alta Partners (USA), Biotech Fund Flanders (Belgium), Gilde Investment Management (The Netherlands), GIMV (Belgium), KBC (Belgium), Sofinnova Partners (France), and SR One (USA). Basic Nanobody[®] patents were contributed by its founding institutions VIB and VUB (Vrije Universiteit Brussel).

Contacts

Media Relations for Ablynx:

Mary Clark, Director
Capital MS&L
t : +44 (0)20 7307 5336
m: +44 7713 335171
e : mary.clark@capitalmsl.com

Halina Kukula
Capital MS&L
t : +44 (0) 20 7307 5340
e: halina.kukula@capitalmsl.com

At Ablynx:

Dr. Edwin Moses
Chairman and CEO
t : +32 (0)9 241 11 51
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Eva-Lotta Allan
Chief Business Officer
t : +32 (0)9 261 06 35
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan@ablynx.com